Puma Biotechnology (PBYI) Lifted to Buy By Research Firm Zacks – Insider Tradings

Research Firm Zacks boosted Puma Biotechnology (NYSE:PBYI) from a hold recommendation to a buy recommendation in a study note released on Early Thur, Jun 8th. Research Firm Zacks presently has $89.00 price objective on the biopharmaceutical firms shares.

Several stock researchers also recently released study analysis regarding the company. Citigroup boosted Puma Biotechnology to a buy recommendation and fixed a $105.00 price objective on the company shares in a study report on Sunday, May 28th. Stifel Nicolaus reissued a buy recommendation and gave a $105.00 target price on the stock of Puma Biotechnology in a study report on early Mon, Jun 5th. J P Morgan Chase & Co reaffirmed an overweight recommendation and given a $89.00 target price on the stock of Puma Biotechnology in a study report on early Tue, Jun 6th. Royal Bank Of Canada upped their target price on the stock of Puma Biotechnology from $60.00 to $88.00 and issued the shares a sector perform recommendation in a analysis report on Tue, Jun 6th. Lastly, Cowen and Company boosted Puma Biotechnology from a neutral recommendation to an outperform recommendation and fixed a $91.00 price objective on the company shares in a study analysis published on early Thur, May 25th. 1 equity analyst has recommended the share with a sell recommendation, two have published a hold recommendation and six have issued a buy recommendation to The corporation. the share presently has a consensus rating of Buy and an consensus price target of $86.94.

According to Research firm Zacks, Puma Biotechnology Stocks soared quite recently following an FDA advisory committee recommended approval of its lead pipeline candidate, neratinib for the treatment of HER2-positive breast cancers. As a development-stage company, Puma does not have any approved product in its portfolio yet. Thus, The corporation is totally dependent on its lead candidate neratinib for growth. With the latest FDA panel win, the approval of neratinib seems highly likely. An approval would be a huge rise for The corporation issued the immense commercial possible in the recipient market. However, dependence on the successful development and of a single candidate May severely hurt the firms growth prospects in case of any adverse development or regulatory setback. stocks of the company have outperformed the industry in the past 52 week.

Puma Biotechnology (PBYI) started trading at 85.95 on Early Thur. the firms valuation is $3.18 B. the company has 50 day SMA of $59.74 and a two hundred SMA of $42.39. Puma Biotechnology has a 52 week low of $27.64 and a 52 week high of $92.00.

Puma Biotechnology (NYSE:PBYI) previously issued its earnings report on early Wed, May 10th. The biopharmaceutical business posted ($1.97) EPS for the period, reaching the Zacks average forecast of ($2.06) by $0.09. on consensus, financial stock experts expect that Puma Biotechnology to post ($8.50) EPS for the present financial year.

In other Puma Biotechnology news, large stockholder Adage Capital Partners Gp, L.L unloaded 507,128 stocks of the firms shares in a trade dated Mon, Jun 5th. The stock was unloaded at a price range of of $87.84, amounting $44,546,123.52. The information was declared in a document with the securities and exchange commission, which is accessible through this link. executive have unloaded a total of 1,990,088 stocks of company shares valued $157,553,113 in the previous 90 days. corporate executives has an ownership of 22.70% of the firms stock.

Hedge funds have lately adjusted their holdings of The corporation. Bank of Montreal Can bought a new stake in stocks of Puma Biotechnology during the Q1 worth at $195,000. Alambic Investment Management bought a new stake in stocks of Puma Biotechnology during the Q1 worth at $201,000. Parametric Portfolio Associates bought a new stake in stocks of Puma Biotechnology during the Q1 worth at $257,000. Perceptive Advisors bought a new stake in stocks of Puma Biotechnology in Q4 which is worth at $225,000. Lastly, Weiss Multi Strategy Advisers bought a new stake in stocks of Puma Biotechnology during the Q1 worth at $335,000. investment firms and many large funds has an ownership of 80.98% of the firms stock.

About Puma Biotechnology

Puma Biotechnology, is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The corporation focuses on in-licensing the development and commercialization rights to over around three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

The rest is here:
Puma Biotechnology (PBYI) Lifted to Buy By Research Firm Zacks - Insider Tradings